Gastrointestinal Stromal TumorsNCT03602092
Observational Registry Data on GIST Patients
An observational study of Gastrointestinal Stromal Tumors, run by National Health Research Institutes, Taiwan at 1 site in Taiwan.
Trial summary
This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan. Read more about this study
- Who is it for?
- Ages 20 years and older
- Conditions the study is for
- Gastrointestinal Stromal Tumors
- What is being tested?
- Observation
- How many people
- 966 participants
- Where
- 1 siteTaiwan
- Study dates
- 16 Oct 2018to 31 Dec 2025
- How long will I take part?
- 7 Years
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients diagnosed with Gastrointestinal Stromal Tumor
Who may be able to join
- Patients diagnosed with Gastrointestinal Stromal Tumor
- ≥20 years old
- Histology-confirmed GIST between 01 January 2010 and 31 December 2020.
- Patient with prospective data collection: Willing to provide singed inform-consent as per local regulatory requirements.
Who cannot join
- Inability and unwillingness to give informed consent if required by site ethic committee.
- Patient that is unlikely candidate to obtain long-term follow-up information for reasons of unavailability or with severe concomitant illnesses per investigator judgement
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Observational Registry: Nationwide Data Collection on Gastrointestinal Stromal Tumors (GISTs) Patients (Taiwan GISTs Registry)
This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
Read the detailed description
Research question and objectives:
This study is to collect and describe real-world data for Taiwanese GIST on:
- Prevalence and demographic characteristics of Taiwanese GIST
- Treatment pattern of GIST therapies
- Bio-marker and/or gene expression characteristics of Taiwanese GIST
- Treatment outcome of TKI therapies, including recurrence-free, progression-free and overall survival
- Safety profile for TKI therapies
Study design: Retrospective and prospective observational cohort study Population: Taiwan GIST patients during 01 January 2010 to 31 December 2020 Data sources: Medical records and investigator-established data bank Study size: Data from up to 3,000 eligible subjects will be collected Data analysis: Descriptive statistics for longitudinally assess nationwide trends on current and evolving diagnostic, treatment, and outcome measures in the GIST population and estimate the prevalence of GIST in Taiwan.
Milestones: Interim report before 31 December 2018 and final study report before 30 June 2026.
- Conditions
- Gastrointestinal Stromal Tumors
- Being tested
- Observation
- Medical subject headings
- Gastrointestinal Stromal Tumors
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ObservationOther
This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
What is being measured
The primary outcome is the main question the study is designed to answer.
To establish the database for GIST
By register the clinical presentation, diagnostic, stage, treatment and clinical outcome of GIST patients.
Measured: From date of registration to 31 December 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jul 2018
- Study start16 Oct 2018
- Primary completion31 Dec 2025
- Study completion31 Dec 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastrointestinal Stromal TumorsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 966 participants (actual)
- Target duration
- 7 Years
Sponsor and investigators
- Lead sponsor
- National Health Research Institutes, Taiwan
- Sponsor type
- University, hospital or other
- Collaborators
- Taipei Veterans General Hospital, Taiwan, National Taiwan University Hospital, China Medical University Hospital, Changhua Christian Hospital, Chang Gung Memorial Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University, Taichung Veterans General Hospital
- Responsible party
- Sponsor
- Investigators
- Tsang-Wu Liu, M.D, Study director, Taiwan Cooperation Organization Group,NHRI,Taiwan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03602092
- Sponsor's protocol ID
- T1218
- Status last verified
- Sep 2026
- First submitted
- 16 Jul 2018
- Last updated
- 15 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Observational Registry: Nationwide Data Collection on Gastrointestinal Stromal Tumors (GISTs) Patients (Taiwan GISTs Registry)
- ClinicalTrials.gov ID
- NCT03602092
- Acronym / sponsor ID
- T1218
- Conditions
- Gastrointestinal Stromal Tumors
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 966 participants (actual)
- Lead sponsor
- National Health Research Institutes, TaiwanUniversity, hospital or other
- Collaborators
- Taipei Veterans General Hospital, Taiwan, National Taiwan University Hospital, China Medical University Hospital, Changhua Christian Hospital, Chang Gung Memorial Hospital, National Cheng-Kung University Hospital, Kaohsiung Medical University, Taichung Veterans General Hospital
- Study start
- 16 Oct 2018 (actual)
- Primary completion
- 31 Dec 2025 (actual)
- Study completion
- 31 Dec 2025 (actual)
- First posted
- 26 Jul 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan.
Detailed description
Research question and objectives:
This study is to collect and describe real-world data for Taiwanese GIST on:
- Prevalence and demographic characteristics of Taiwanese GIST
- Treatment pattern of GIST therapies
- Bio-marker and/or gene expression characteristics of Taiwanese GIST
- Treatment outcome of TKI therapies, including recurrence-free, progression-free and overall survival
- Safety profile for TKI therapies
Study design: Retrospective and prospective observational cohort study Population: Taiwan GIST patients during 01 January 2010 to 31 December 2020 Data sources: Medical records and investigator-established data bank Study size: Data from up to 3,000 eligible subjects will be collected Data analysis: Descriptive statistics for longitudinally assess nationwide trends on current and evolving diagnostic, treatment, and outcome measures in the GIST population and estimate the prevalence of GIST in Taiwan.
Milestones: Interim report before 31 December 2018 and final study report before 30 June 2026.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 7 Years
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients diagnosed with Gastrointestinal Stromal Tumor
Key inclusion criteria (4 listed)
- Patients diagnosed with Gastrointestinal Stromal Tumor
- ≥20 years old
- Histology-confirmed GIST between 01 January 2010 and 31 December 2020.
- Patient with prospective data collection: Willing to provide singed inform-consent as per local regulatory requirements.
Key exclusion criteria (2 listed)
- Inability and unwillingness to give informed consent if required by site ethic committee.
- Patient that is unlikely candidate to obtain long-term follow-up information for reasons of unavailability or with severe concomitant illnesses per investigator judgement
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ObservationThis is a longitudinal, multi-center, registry study, collecting data via a web-based portal in patients with GIST (Gastrointestinal Stromal Tumor) from hospitals in Taiwan. | Other | – |
Primary outcome
To establish the database for GIST
Time frame: From date of registration to 31 December 2025
By register the clinical presentation, diagnostic, stage, treatment and clinical outcome of GIST patients.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Gastrointestinal Stromal Tumors
RecruitingPhase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer
RecruitingPhase 3
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Gastrointestinal Stromal Neoplasms
RecruitingPhase 2
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
Gastrointestinal Stromal Tumors
Active, not recruitingPhase 2
A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments
Unresectable Gastrointestinal Stromal Tumor (GIST), Locally Advanced Gastrointestinal Stromal Tumor (GIST)
RecruitingPhase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Tsang-Wu Liu, M.D study director
Taiwan Cooperation Organization Group,NHRI,Taiwan
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastrointestinal Stromal Tumors, run by National Health Research Institutes, Taiwan at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To establish the database for GIST (time frame: From date of registration to 31 December 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026.